Modified residual SYNTAX score and clinical outcomes in patients with multivessel disease undergoing percutaneous coronary intervention

EuroIntervention. 2017 May 15;13(1):87-96. doi: 10.4244/EIJ-D-16-00685.

Abstract

Aims: We sought to determine a reasonable level of revascularisation using the modified residual SYNergy between percutaneous coronary intervention (PCI) with TAXus and cardiac surgery (SYNTAX) score in patients undergoing PCI.

Methods and results: In 3,460 patients with multivessel disease receiving drug-eluting stents, residual SYNTAX score (rSS) was calculated for lesions with ≥50% diameter stenosis in vessels ≥1.5 mm after PCI. The "modified" rSS (mrSS) was determined by counting lesions with ≥70% diameter stenosis in vessels ≥2.5 mm only. Patients were categorised into the complete revascularisation (CR) group (rSS=0), the incomplete revascularisation (ICR) group (mrSS >0), or the reasonable ICR (R-ICR) group (rSS >0, but mrSS=0). After propensity matching, the R-ICR group (n=1,129) had a comparable risk of all-cause death (HR 0.80, 95% CI: 0.56-1.15, p=0.24) and a composite of all-cause death, myocardial infarction (MI), or repeat revascularisation (HR 0.91, 95% CI: 0.74-1.14, p=0.41) compared with the CR group (n=637) at three years. In separate propensity matching analyses, patients with R-ICR (n=1,280) had a lower risk of all-cause death (HR 0.73, 95% CI: 0.55-0.97, p=0.03) and a composite of all-cause death, MI, or repeat revascularisation (HR 0.68, 95% CI: 0.57-0.82, p<0.001) than those with ICR (n=837) at three years.

Conclusions: Complete revascularisation of lesions with ≥70% diameter stenosis in vessels ≥2.5 mm is better than ICR, and is a reasonable goal for patients with multivessel disease.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Coronary Angiography / adverse effects
  • Coronary Artery Disease / surgery
  • Drug-Eluting Stents* / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / etiology*
  • Percutaneous Coronary Intervention* / adverse effects
  • Risk Assessment
  • Treatment Outcome